Schrödinger has discontinued development of SGR-2921, a CDC7 inhibitor for acute myeloid leukemia (AML), after two patients died in a Phase I dose-escalation study, with the drug considered a contributing factor. Despite early signs of monotherapy activity, safety concerns have halted progress, underscoring the complexities in developing novel oncology therapies and the critical importance of patient safety in early clinical trials.